Association of serum fetuin-A levels with heart valve calci cation and other biomarkers of in ammation among persons with acute coronary syndrome Abstract Purpose: Fetuin-A is a multifunctional hepatic secretory protein that inhibits dystrophic vascular and valvular calci cation. Our aim was to evaluate the relationship among fetuin-A levels, heart valve calci cation and other biomarkers of in ammation in patients with acute coronary syndrome (ACS).
Atherosclerotic coronary artery disease is the major cause of mortality and morbidity in developed countries. Some risk factors, such as hypertension, smoking, obesity, diabetes and high LDL cholesterol levels, have been identi ed for atherosclerosis, but in more than 50% of patients who had atherosclerotic disease, none of these risk factors has been detected. us, factors other than these traditional risk factors may play a role in the atherosclerotic process.
A correlation between heart valve calci cation and acute coronary syndrome has been known for a long time. Mitral annular calci cation (MAC), a brotic, degenerative calci cation of the mitral annulus, is caused by age, hypertension and chronic renal failure [1, 2] . Like MAC, aortic valve calci cation, de ned as aortic stenosis (AS), is also a ected by the same factors. Since the risk factors such as hypertension, hyperlipidemia, diabetes and obesity are common risk factors for MAC and coronary artery disease [3, 4] , MAC can be considered as an indicator of the subclinical atherosclerosis. Furthermore, it has been shown that vascular calci cation is a risk factor for coronary artery disease [5, 6] .
Fetuin-A (α2 Heremans Schmid Glycoprotein, Ahsg) is a 59 kD glycoprotein that is secreted mainly from the liver in adults, and which has a serum concentration of 0.5-1 g/L [7] . Fetuin-A has recently been described as an inhibitor of vascular and valvular calci cation and it is a major inhibitor of calcium and phosphate precipitation. At the same time fetuin-A regulates the bone mineralization by preventing the ectopic calcication [7] .
Recent studies have shown fetuin-A clustered inside the calci ed vascular lesions of patients with renal failure [8] . Low serum fetuin-A levels and lower activity were detected in dialysis patients [8] . Wang et al. [9] reported an evident correlation among low levels of fetuin-A, increased vascular calci cation and in ammation and an inverse correlation between the serum levels of this glycoprotein and the ratio of cardiovascular deaths in dialysis patients. e correlation between in ammation and atherosclerosis were studied in patients with acute coronary syndrome [8] .
e main markers of in ammation are the acute phase reactants. In acute coronary syndrome patients, positive acute phase reactants include the erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, ferritin, brinogen and high sensitive-C-reactive protein (hs-CRP). In addition to these reactants, the most used parameter of the negative acute phase is albumin. It has been argued that in acute in ammation, the serum level of fetuin-A decreases, as well as the level of albumin, and it has been suggested that fetuin-A should be considered as a negative acute phase reactant. It has been proved that the concentration of fetuin-A decreases during in ammation and trauma [10] . In addition, there is an inverse correlation between fetuin-A levels and the levels of the proin ammatory cytokines such as IL-1β, IL-6 and TNF-α [11] and an inverse correlation between low levels of fetuin-A and CRP, which is a marker of in ammation in patients with chronic renal failure who were on stable haemodialysis [12] .
An inverse association was detected between serum fetuin-A concentrations and MAC among a cohort with coronary heart disease and without severe kidney disease [13] . A similar association was observed between fetuin-A and AS, but was limited to participants without diabetes mellitus [13] . ese data are consistent with the hypothesis that fetuin-A functions as an important inhibitor of dystrophic valvular calci cation among persons with coronary heart disease, and that this function does not require the presence of kidney disease or other traditional cardiovascular risk factors [13] .
It has been hypothesized that fetuin-A is protective against ischemia in cardiomyocytes. Low levels of fetuin-A concentration have a direct deteriorating e ect on myocardial functions. Catecholamine resistance and tolerance to ischemia and diastolic functions were found to be reduced in the hearts of fetuin knock-out mice [14] .
e aim of this study was to evaluate the relationship among serum fetuin-A levels, heart valve calci cation and other biomarkers of in ammation in patients with coronary heart disease.
Materials and Methods

Demographic features of patients
A total of 95 patients, 68 men and 27 women, with acute coronary syndrome (ACS) between the ages of 37-84 years were included in the study. Our control group was 32 healthy men and 49 healthy women between the ages of 32-76 years. Acute coronary syndrome was diagnosed according to universal denition of myocardial infarction [15] . e patients were asked for their gender, medical history (type 2 DM, HT, smoking and medications) and measured for systolic blood pressure (SBP), diastolic blood pressure (DBP) and glomerular ltration rate (GFR).
Exclusion criteria included trauma history, major surgical history, chronic in ammatory disease, acute infection, chronic kidney disease with a creatinine clearance under 15 mM/min, alcoholic hepatitis, acute toxic hepatitis, chronic autoimmune hepatitis, fatty liver, alcoholic and primer biliary cirrhosis, lung disease, known liver disease, known malignancy, known rheumatic heart valve disease, congenital heart disease including bicuspid aorta, dilated cardiomyopathy and known osteoporosis.
Serum preparation
Blood was drawn in the morning a er 12 -14 hours of fasting. Serum was obtained a er at least 30 minutes of clotting by centrifugation at 2500xg for 15 minutes. Serum was used directly or stored at -80 0 C until assayed. All icteric or haemolytic blood samples were discarded. All parameters were analyzed in all samples together in a single batch at the termination of the experimental protocol (control and patient samples were analysed in the same batch).
Measurement of serum fetuin-A levels
Serum fetuin-A levels in the patients with acute coronary syndrome were measured at the 48th hour and in the control group in the serum obtained from the venous blood. A commercial kit (Assaypro, USA, cat no: EG 63501-1), based on a quantitative sandwich ELISA, was used and results was determined with ELX 800 UV version ELISA reader and calculated in grams per liter. Mean intra-assay and inter-assay coe cients of variation were less than 4.9 % (n:10) and 6.7 %(n:10).
Measurement of other biochemical parameters
Levels of serum glucose, urea, creatinine, total cholesterol, triglyceride, HDL, LDL, parathyroid hormone (PTH), calcium, phosphorus, white blood cell (WBC) count, ferritin, albumin, brinogen, hs-CRP, creatine kinase-MB(CK-MB), troponin T and erythrocyte sedimentation rate (ESR) were measured in the patient and control groups using the same biochemistry laboratory in our hospital.
Transthoracic echocardiography
Echocardiographic examinations of all patients were done during rest using a Vivid-3 (General Electrics) echocardiography machine with a 3.5 mHz probe. Two dimensional echocardiographs and Doppler examinations were done in all standard positions. Echocardiographical examinations of all patients were performed by one experienced cardiologist who was not informed about the clinical status of the patients. In the images of paracentral long axis, apical four ventricles and paracentral short axis, mitral annular calci cation (MAC) was de ned as a hyperechoic formation inside the atrioventicular junction and mitral posterior lea et [16, 17] . Aortic calci cation was also de ned as increased thickness and bright echoes of the valve lea ets. e pressure gradient measured on the aortic valve was calculated as a maximum and average gradient according to the Bernoulli equation and the area of the aortic valve was calculated according to the continuity equation principle [18, 19] . Aortic stenosis was de ned as the current velocity measured on the aortic valve above 2.0 m/s, the maximum gradient above 15 mmHg and aortic valve area under 2 cm 2 [20] .
Statistical analysis
Statistical analyses (Mann-Whitney U-test, Student t test) were performed with SPSS 17 (Statistical Package for Social Sciences). e di erence in gender, smoking, HT, DM, calcium channel blocker use, MAC and aortic stenosis groups were analyzed by the Chi-square test. Pearson correlation test was used for correlating fetuin-A and the biochemical parameters, age, BMI, systolic and diastolic pressure and GFR. Multivariate logistic regression model was performed to determine the e ect of independent risk factors for acute coronary syndrome. P-values < 0.05 were considered signi cant.
Results
Clinical data of patients are summarized in Table 1 . In the patient group, the percentage of men (p<0.001), smoking (p<0.001), hypertension (p<0.001), diabetes mellitus (p<0.001) and calcium channel blocker usage (p<0.01) was signi cantly higher than in the control group.
ere was no statistically di erence (p > 0.05) in heart valve calci cation among the patients and healthy controls [ Table 2 ].
In Table 3 , the averages of age (p<0.001) and the diastolic and systolic arterial pressures (p<0.001) are statistically higher in the patient group than in the healthy controls. ere was no statistically di erence in BMI (p>0.05), GFR (p>0.05), cholesterol and LDL level averages (p>0.05) among the patient group and the healthy controls. Even though the triglyceride levels were signi cantly higher in the patient group (p<0.01), the HDL levels were signi cantly higher in healthy controls (p<0.001). In the patient group, the averages of fasting blood glucose levels (p<0.001), urea and creatinine levels (p<0.001) were statistically higher than the healthy control group, yet the urea and creatinine levels were within the normal range. e levels of CKMB (p<0.001), WBC (p<0.001), brinogen (p<0.001), ESR (p<0.001) and ferritin (p<0.01) were signicantly higher in the patient group than the control group, whereas the average calcium and of albumin levels were higher (p<0.001) in the healthy controls than the patient group.
ere was no signi cant di erence between PTH and phosphorus levels among two groups. e average of hs-CRP levels were statistically higher (p<0.001) in the patient group but the averages of fetuin-A levels were signi cantly lower (0.76 ± 0.23 and 1.10 ± 0.45 g/L, respectively; p < 0.001) in the patient group than the control group. In Table 4 , there was a negative correlation between serum urea (r = -0.377; p = 0.000) and creatinine (r = -0.232; p = 0.024) levels and fetuin-A in the patients. ere was a negative correlation between WBC (r = -0,156; p = 0.132), ESR (r = -0.214; p = 0.037), hs-CRP (r = -0, .220; p = 0.032) levels and fetuin-A in patients; however, there was a positive correlation between albumin and fetuin-A (r = 0.362; p = 0.000). Serum fetuin-A (r = -0.29, p < 0.01) showed a negative moderate correlation with age in the patients and in both groups combined [ Table 4 ].
Fetuin-A was lower in patients with mitral annular (p = 0.007) and aortic (p = 0.001) valve calci cation [ Table 5 ].
In the patient group and in total, there is a negative weak correlation between fetuin-A levels and age (r=-0,291 p<0.01 r=-0,327 p<0.001). ere is a negative correlation between urea and creatinine levels and fetuin-A but there is a positive correlation between GFR and fetuin-A in patient group. In patient group there is a positive correlation between triglyceride levels and fetuin-A. ere is a positive correlation between fetuin-A and albumin and calcium levels while there is a negative correlation between ESR, WBC and fetuin-A.
Fetuin A is negatively correlated with hs-CRP and troponin T in patient group. Among patients with aortic stenosis, fetuin-A levels are found to be lower but with only a weak signi cance. Between MAC and fetuin-A, there was a lower correlation with a weak signi cance.
e results of multivariate logistic regression analysis, including OR for each of the demographic factors, biochemical parameters and fetuin-A are presented in [ 
Discussion
In our study, it was found that, serum fetuin-A levels decreased, regardless of the degree of calci cation of the heart valve, in patients with acute coronary syndrome. A er myocardial infarction, the serum fetuin-A levels were negatively correlated with hs-CRP levels, which is an acute phase reactant. In other words, fetuin-A may be a negative acute phase reactant showing a diagnostic and prognostic importance in patients with acute coronary syndrome. In ammation is a common feature of all di erent stages of atherosclerosis. Fetuin-A is an anti-in ammatory mediator that is produced by the liver and participates in macrophage deactivation. Epidemiological studies, demonstrating the correlation between fetuin-A and dystrophic calci cation, which have been performed on the patients with end-stage renal failure, showed a correlation between low level of serum fetuin-A, valvular and vascular calci cation and mortality [9, 21, 22] . Ix et al. [13] have observed an inverse association between fetuin-A and mitral annular calci cation among individuals with coronary heart disease. An inverse association was also observed between fetuin-A and calsi c aortic stenosis among participants without diabetes mellitus. in another study performed by the same researchers, serum fetuin-A levels of the coronary heart disease patients with normal and moderate renal dysfunction were found to be similar [23] . In this study, patients with coronary heart disease, with normal renal function and healthy patients as the control group, were examined and fetuin-A levels of the control group were determined to be signi cantly higher than of the patient group. No statistically signi cant di erence was found between the patient and the control groups in terms of MAC or AS. Serum fetuin-A levels of the patients without MAC and AS, and of the control groups, were found to be statistically higher.
Although no signi cant di erence between the control and patient groups was determined in terms of MAC and AS, higher level of serum fetuin-A in the control group compared with the patients with acute coronary syndrome raises a new question: why does serum fetuin-A level decrease in the patients with acute coronary syndrome? In a study performed by Merx et al. [14] on the hearts of fetuin-A knockout mice, an increase in cardiac brosis and calci cation, impaired diastolic function, tolerance to the ischemia and catecholamine resistance were detected. In ammation is the main predictor of the plaque rupture mechanism in patients with ST segment elevation myocardial infarction (STEMI). Following necrosis, inammation is maintained in the residual myocardium. Results of this may be both useful (such as improvement and recovery in functions) and harmful (such as acute cardiac rupture, chronic dilatation, heart failure) [24] .
Impairment of the balance between the anti-in ammatory and proin ammatory mediators can be harmful. Antiin ammatory mediators decrease the production of the proinammatory cytokine production through several di erent ways [25] . On the other hand, fetuin-A is considered as a preformed cofactor that opsonizes the cationic macrophage deactivating molecules [26] . During in ammation, the proin ammatory cytokines, whose synthesis is generally inhibited by fetuin-A, block the synthesis of fetuin-A in the liver [11] . Decreased fetuin-A level in the circulation a ects, and thereby prevents, the activities of several anti-in ammatory molecules [27] ; however, in the presence of acute coronary syndrome, low serum fetuin-A concentration facilitates ongoing in ammatory processes and causes over-production of the cardiotoxic cytokines such as TNF [11, 28] . is causes patients to be exposed to remodeling of le ventricle and to a high risk of relapse of acute coronary syndrome. Postinfarct in ammation reaches to its highest level on the 3rd day. In this study, serum fetuin-A levels were measured in patients on the 2nd day postinfarction. Fetuin-A concentration re ects the stage of inammatory imbalance, since fetuin is activated as a result of the interaction between proin ammatory and anti- in ammatory cytokines. is crucial nding causes the fetuin-A level to be considered as a clinical risk score. Fetuin-A acts as a negative acute phase reactant and its level decreases in chronic in ammation [10] . In ammation plays a major role in the pathophysiology of coronary artery disease and atherosclerosis is de ned as a chronic in ammatory disease [29] . Many pro-in ammatory markers have been shown to contribute to the development of atherosclerosis [30] . In addition, anti-in ammatory cytokines, produced during inammation, also play an important role in controlling the inammatory response. e results from di erent studies regarding the relationship between the levels of fetuin-A, which is an anti-in ammatory cytokine, and the presence of cardiovascular diseases are controversial [31, 32] . High levels of serum fetuin-A have been found to be associated with a high risk of myocardial infarction and ischemic stroke [32] . In our study, the fetuin-A levels in patients with acute coronary syndrome are lower than in the control group. Acute myocardial infarction is a pro-in ammatory condition, and the CRP levels have been shown to increase in patients with ACS [33] . Although it is an anti-in ammatory marker, fetuin-A can stimulate the in ammatory response by increasing the production of cardiotoxic cytokines such as tumor necrosis factor [34] . It has also been shown that fetuin-A induces the expression of cytokine in human monocytes and reduces the expression of adiponectin, which has atheroprotective properties in animals [32] . Basar et al. (35) have found low fetuin-A levels to be associated with an impaired coronary ow in patients with STEMI who underwent primary percutaneous coronary intervention. In the same study, the one year major adverse cardiac events (MACE) were higher in patients with low fetuin-A levels than those with high fetuin-A levels. Similarly, in a recent study, hs-CRP, which is a positive acute phase reactant, was associated with an increase in mortality in patients with ACS [36] . In another study of ACS, Lim et al. [37] have demonstrated that low serum fetuin-A levels in patients with STEMI were associated with a poor prognosis. As determined in our study, the fetuin-A levels in patients with ACS, as an indicator of the severity of the inammatory response, are low and may indicate a poor prognosis.
ere is also an inverse correlation between fetuin-A and CRP levels and between fetuin-A and in ammation [9] . In our study, a statistically signi cant negative correlation between ESR, WBC and hs-CRP levels and fetuin-A was determined in patients with ACS and overall.
ese results support the theory that fetuin-A is a negative acute phase reactant. e negative correlation between fetuin-A and the positive acute phase reactants is also consistent with this theory.
In our study, MAC was established in 12 patients with ACS, while AS was detected in eight patients. In the control group, MAC was also detected in nine patients and AS in ve patients. No statistically signi cant di erence between these groups was detected in terms of coronary valve calci cation; however, in patients with mitral annular calci cation and aortic valve calci cation, the serum fetuin-A levels were lower than in patients without detected calci cation of the heart valves.
is nding is consistent with the results of Ix et al. [13] , which showed that MAC and AS and low fetuin-A level are related to each other in patients with coronary artery disease. In other words, fetuin-A is an important inhibitor of dystrophic calci cation, and with decreasing fetuin-A serum levels, the probability of the calci cation of the heart valves increases. In patients with end-stage renal failure, correlations were determined between low level fetuin-A concentration and increased vascular and valvular calci cation, increased cardiovascular events and mortality. It is unknown whether there is an association between the dystrophic calci cations and serum fetuin-A levels in other populations [9, 21, 22, 24] .
Our study has several limitations. One of the major limitations of the study is the relative scarcity of the patients with ACS, compared with the general patient population. In addition, the relationship between the success of the reperfusion therapy and the serum fetuin-A levels was not assessed. Similarly, the relationship between serum fetuin-A levels and the parameters such as the Syntax and Gensini scores, which show the extent of atherosclerosis and the complexity of the lesion, was not assessed. Another important limitation is the lack of the assessment of the relationship between the serum fetuin-A levels and in-hospital MACE and mortality. In addition, the lack of the assessment of the relationship between the serum fetuin-A levels and the short-and the long-term prognosis in patients with ACS is another limitation.
Conclusion
Serum fetuin-A level may prove to be useful as a marker of inammation and calci cation for cardiovascular events. Since the serum levels may vary in metabolic syndrome, DM, hepatic steatosis, in ammatory diseases and in general healthy population, it is obvious that further study is required. Further studies are also needed for patients with ACS. Future detailed studies will show us the importance of fetuin-A and its functions in human body in di erent metabolic, in ammatory pathways.
